In clinical practice, the most commonly used molecular classification of BC is St Gallen 2015 International Expert Consensus, based on the expression of an estrogen receptor (ER), progesterone receptor (PR), a receptor for human epidermal growth factor 2 (HER2) in cancer cells and Ki67 protein, which reflects proliferation levels [4, 5]. This evidence concerns the gene PGR and breast cancer.